Mabion Valuation

Is MAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MAB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MAB?

Key metric: As MAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MAB. This is calculated by dividing MAB's market cap by their current earnings.
What is MAB's PE Ratio?
PE Ratio	14.7x
Earnings	zł10.24m
Market Cap	zł150.96m

MAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	2.8x
PEG Ratio	1.3x

Price to Earnings Ratio vs Peers

How does MAB's PE Ratio compare to its peers?

The above table shows the PE ratio for MAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	39.4x
SVE Synthaverse	74.5x	n/a	zł331.3m
GEN Genomed Spólka Akcyjna	42.2x	n/a	zł37.0m
BGD Biogened	15.6x	n/a	zł76.1m
ALGEN genOway Société anonyme	25.4x	n/a	€31.9m
MAB Mabion	14.7x	11.8%	zł151.0m

Price-To-Earnings vs Peers: MAB is good value based on its Price-To-Earnings Ratio (14.7x) compared to the peer average (39.4x).

Price to Earnings Ratio vs Industry

How does MAB's PE Ratio compare vs other companies in the European Biotechs Industry?

4 Companies	Price / Earnings	Estimated Growth	Market Cap

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: MAB is good value based on its Price-To-Earnings Ratio (14.7x) compared to the European Biotechs industry average (29.1x).

Price to Earnings Ratio vs Fair Ratio

What is MAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	14.7x
Fair PE Ratio	27x

Price-To-Earnings vs Fair Ratio: MAB is good value based on its Price-To-Earnings Ratio (14.7x) compared to the estimated Fair Price-To-Earnings Ratio (27x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MAB forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	zł9.34	zł8.17 -12.6%	20.2%	zł10.00	zł6.00	n/a	3
Jan ’26	zł8.90	zł8.17 -8.2%	20.2%	zł10.00	zł6.00	n/a	3
Dec ’25	zł12.10	zł11.50 -5.0%	45.3%	zł18.50	zł6.00	n/a	3
Nov ’25	zł12.42	zł15.50 +24.8%	14.7%	zł18.50	zł13.00	n/a	3
Oct ’25	zł16.38	zł15.50 -5.4%	14.7%	zł18.50	zł13.00	n/a	3
Sep ’25	zł18.54	zł15.83 -14.6%	14.2%	zł18.50	zł13.00	n/a	3
Aug ’25	zł17.86	zł15.83 -11.3%	14.2%	zł18.50	zł13.00	n/a	3
Jul ’25	zł17.14	zł15.83 -7.6%	14.2%	zł18.50	zł13.00	n/a	3
Jun ’25	zł16.66	zł15.83 -5.0%	14.2%	zł18.50	zł13.00	n/a	3
May ’25	zł16.28	zł15.83 -2.7%	14.2%	zł18.50	zł13.00	n/a	3
Apr ’25	zł16.30	zł15.57 -4.5%	7.3%	zł16.70	zł14.00	n/a	3
Mar ’25	zł16.99	zł15.57 -8.4%	7.3%	zł16.70	zł14.00	n/a	3
Feb ’25	zł18.13	zł15.57 -14.1%	7.3%	zł16.70	zł14.00	zł9.34	3
Jan ’25	zł18.15	zł15.57 -14.2%	7.3%	zł16.70	zł14.00	zł8.90	3
Dec ’24	zł21.48	zł15.57 -27.5%	7.3%	zł16.70	zł14.00	zł12.10	3
Nov ’24	zł17.00	zł15.35 -9.7%	8.8%	zł16.70	zł14.00	zł12.42	2
Oct ’24	zł16.99	zł15.35 -9.7%	8.8%	zł16.70	zł14.00	zł16.38	2
Sep ’24	zł16.79	zł15.35 -8.6%	8.8%	zł16.70	zł14.00	zł18.54	2
Aug ’24	zł18.00	zł15.35 -14.7%	8.8%	zł16.70	zł14.00	zł17.86	2
Jul ’24	zł16.44	zł15.35 -6.6%	8.8%	zł16.70	zł14.00	zł17.14	2
Jun ’24	zł17.00	zł15.35 -9.7%	8.8%	zł16.70	zł14.00	zł16.66	2
May ’24	zł18.45	zł14.75 -20.1%	5.1%	zł15.50	zł14.00	zł16.28	2
Apr ’24	zł17.82	zł15.75 -11.6%	1.6%	zł16.00	zł15.50	zł16.30	2
Mar ’24	zł20.69	zł15.75 -23.9%	1.6%	zł16.00	zł15.50	zł16.99	2
Feb ’24	zł22.64	zł15.75 -30.4%	1.6%	zł16.00	zł15.50	zł18.13	2

Analyst Price Target

Consensus Narrative from 3 Analysts

zł8.17

Fair Value

14.4% overvalued

Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/01 09:27
End of Day Share Price	2025/01/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mabion S.A. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamil Kliszcz	Biuro maklerskie mBanku
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku
Pawel Sugalski	ING Groep NV